Goldman Sachs’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.09B | Buy |
10,605,842
+3,400,181
| +47% | +$656M | 0.24% | 63 |
|
|
2025
Q4 | $1.32B | Buy |
7,205,661
+369,786
| +5% | +$64.9M | 0.16% | 106 |
|
|
2025
Q3 | $1.05B | Buy |
6,835,875
+829,844
| +14% | +$126M | 0.13% | 137 |
|
|
2025
Q2 | $839M | Buy |
6,006,031
+115,107
| +2% | +$16.1M | 0.11% | 157 |
|
|
2025
Q1 | $866M | Buy |
5,890,924
+696,625
| +13% | +$101M | 0.14% | 126 |
|
|
2024
Q4 | $681M | Sell |
5,194,299
-828,844
| -14% | -$116M | 0.11% | 167 |
|
|
2024
Q3 | $939M | Sell |
6,023,143
-225,032
| -4% | -$36.3M | 0.15% | 122 |
|
|
2024
Q2 | $975M | Buy |
6,248,175
+105,117
| +2% | +$15.8M | 0.16% | 108 |
|
|
2024
Q1 | $832M | Buy |
6,143,058
+376,319
| +7% | +$49.8M | 0.15% | 133 |
|
|
2023
Q4 | $777M | Buy |
5,766,739
+224,999
| +4% | +$29.2M | 0.14% | 134 |
|
|
2023
Q3 | $751M | Buy |
5,541,740
+241,888
| +5% | +$33M | 0.16% | 118 |
|
|
2023
Q2 | $759M | Buy |
5,299,852
+656,797
| +14% | +$96.6M | 0.16% | 108 |
|
|
2023
Q1 | $645M | Buy |
4,643,055
+767,312
| +20% | +$103M | 0.15% | 121 |
|
|
2022
Q4 | $526M | Buy |
3,875,743
+500,442
| +15% | +$62.8M | 0.13% | 146 |
|
|
2022
Q3 | $370M | Buy |
3,375,301
+172,608
| +5% | +$21.9M | 0.09% | 196 |
|
|
2022
Q2 | $423M | Sell |
3,202,693
-412,818
| -11% | -$54.2M | 0.11% | 147 |
|
|
2022
Q1 | $480M | Buy |
3,615,511
+474,280
| +15% | +$56.9M | 0.1% | 176 |
|
|
2021
Q4 | $366M | Sell |
3,141,231
-2,620,548
| -45% | -$308M | 0.07% | 267 |
|
|
2021
Q3 | $692M | Sell |
5,761,779
-1,553,922
| -21% | -$181M | 0.15% | 122 |
|
|
2021
Q2 | $876M | Buy |
7,315,701
+2,580,108
| +54% | +$283M | 0.2% | 76 |
|
|
2021
Q1 | $471M | Buy |
4,735,593
+615,659
| +15% | +$61.9M | 0.12% | 159 |
|
|
2020
Q4 | $412M | Buy |
4,119,934
+970,499
| +31% | +$103M | 0.11% | 171 |
|
|
2020
Q3 | $345M | Sell |
3,149,435
-821,549
| -21% | -$91.4M | 0.1% | 179 |
|
|
2020
Q2 | $420M | Buy |
3,970,984
+8,222
| +0.2% | +$849K | 0.13% | 141 |
|
|
2020
Q1 | $354M | Buy |
3,962,762
+542,549
| +16% | +$51.1M | 0.12% | 152 |
|
|
2019
Q4 | $341M | Buy |
3,420,213
+100,913
| +3% | +$9.5M | 0.09% | 238 |
|
|
2019
Q3 | $296M | Buy |
3,319,300
+791,527
| +31% | +$68.6M | 0.09% | 243 |
|
|
2019
Q2 | $209M | Sell |
2,527,773
-179,606
| -7% | -$14.1M | 0.06% | 352 |
|
|
2019
Q1 | $219M | Buy |
2,707,379
+1,069,506
| +65% | +$84.3M | 0.07% | 325 |
|
|
2018
Q4 | $124M | Buy |
1,637,873
+150,887
| +10% | +$11.8M | 0.04% | 516 |
|
|
2018
Q3 | $118M | Buy |
1,486,986
+342,045
| +30% | +$25.9M | 0.03% | 661 |
|
|
2018
Q2 | $80.4M | Sell |
1,144,941
-803,232
| -41% | -$57.8M | 0.02% | 891 |
|
|
2018
Q1 | $136M | Buy |
1,948,173
+399,462
| +26% | +$27.7M | 0.03% | 602 |
|
|
2017
Q4 | $107M | Buy |
1,548,711
+50,195
| +3% | +$3.38M | 0.03% | 761 |
|
|
2017
Q3 | $102M | Sell |
1,498,516
-596,877
| -28% | -$37.7M | 0.02% | 798 |
|
|
2017
Q2 | $143M | Buy |
2,095,393
+626,953
| +43% | +$40.9M | 0.04% | 556 |
|
|
2017
Q1 | $91.5M | Buy |
1,468,440
+448,783
| +44% | +$26.1M | 0.02% | 814 |
|
|
2016
Q4 | $55.7M | Buy |
1,019,657
+51,589
| +5% | +$2.93M | 0.02% | 1189 |
|
|
2016
Q3 | $63.6M | Sell |
968,068
-184,099
| -16% | -$12M | 0.02% | 1019 |
|
|
2016
Q2 | $69.6M | Buy |
1,152,167
+147,966
| +15% | +$8.59M | 0.02% | 885 |
|
|
2016
Q1 | $56.6M | Buy |
1,004,201
+169,790
| +20% | +$10.2M | 0.02% | 1007 |
|
|
2015
Q4 | $56.7M | Buy |
834,411
+43,719
| +6% | +$2.87M | 0.02% | 1033 |
|
|
2015
Q3 | $50.3M | Buy |
790,692
+290,269
| +58% | +$19.1M | 0.02% | 1052 |
|
|
2015
Q2 | $31.9M | Buy |
500,423
+115,384
| +30% | +$7.9M | 0.01% | 1455 |
|
|
2015
Q1 | $26.3M | Buy |
385,039
+43,720
| +13% | +$3.04M | 0.01% | 1562 |
|
|
2014
Q4 | $24M | Sell |
341,319
-230,015
| -40% | -$16.5M | 0.01% | 1700 |
|
|
2014
Q3 | $40.8M | Buy |
571,334
+240,381
| +73% | +$17.6M | 0.01% | 1225 |
|
|
2014
Q2 | $24.6M | Sell |
330,953
-201,261
| -38% | -$14.5M | 0.01% | 1639 |
|
|
2014
Q1 | $34.5M | Buy |
532,214
+334,418
| +169% | +$21.6M | 0.01% | 1322 |
|
|
2013
Q4 | $11.7M | Sell |
197,796
-21,288
| -10% | -$1.16M | ﹤0.01% | 2228 |
|
|
2013
Q3 | $11.4M | Sell |
219,084
-54,925
| -20% | -$2.76M | ﹤0.01% | 2121 |
|
|
2013
Q2 | $13M | Buy |
+274,009
| New | +$14M | 0.01% | 1866 |
|
Other funds holding AZN
IA
VCM
VAM
Goldman Sachs's AZN Position: Q1 2026 in Review
Goldman Sachs increased its AstraZeneca (AZN) stake by 47% in Q1 2026, buying an estimated $656M and bringing the position to 10,605,842 shares worth $2.09B. The position accounts for 0.24% of the portfolio, ranked #63.
Goldman Sachs first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Goldman Sachs held 10,605,842 shares of AstraZeneca worth $2.09B as of Q1 2026.
- Goldman Sachs bought 3,400,181 AstraZeneca shares in Q1 2026, an estimated $656M.
- AstraZeneca made up 0.24% of Goldman Sachs's portfolio in Q1 2026, its #63 holding.
- Goldman Sachs first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.